{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T22:26:16Z","timestamp":1793571976854,"version":"4.5.0"},"reference-count":34,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Japan Society for the Promotion of Science","award":["25k13116"],"award-info":[{"award-number":["25k13116"]}],"id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Bio-Medical Materials and Engineering"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetes mellitus is risk factors in implant treatment and maintenance, and it is necessary to consider the effects of diabetes medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study investigates whether oral administration of sodium-glucose cotransporter 2 (SGLT2) inhibitor, affects bone formation after implant placement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 44 Goto-Kakizaki rats were used as a type 2 diabetes model, divided into two groups: the drug administration group (MD) and the non-administration group (GK). A total of 22 Wistar rats were used as the control group (CO). Titanium implants were implanted into the rat tibiae.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Histological and SEM images showed that the GK group had significantly less bone formation than the CO group at both 2 and 4 weeks. No significant differences were observed between groups in serum biochemistry and body weight. Mechanical strength was significantly lower in the GK group than in the CO group at 2 weeks and 4 weeks. Blood glucose levels in the MD group were significantly lower than the baseline values at both 2 weeks and 4 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In a diabetic rat model, the SGLT2 inhibitor restored implant bone formation without side effects. Further detailed research in clinical settings is needed on the effects of diabetes medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09592989261481043","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:24:22Z","timestamp":1789997062000},"page":"275-284","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sodium-glucose cotransporter-2 inhibitor administration recovers peri-implant bone formation in type 2 diabetes: An experimental study using a type 2 diabetes rat model"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6327-8437","authenticated-orcid":false,"given":"Tomohiro","family":"Masuzaki","sequence":"first","affiliation":[{"name":"Fukuoka Dental College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Suehiro","sequence":"additional","affiliation":[{"name":"Kagoshima University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Komabashiri","sequence":"additional","affiliation":[{"name":"Kagoshima University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaharu","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Kagoshima University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Osaka University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119"},{"key":"e_1_3_5_3_2","article-title":"Diagnosis and classification of diabetes mellitus","volume":"35","author":"American Diabetes A","year":"2012","unstructured":"American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35: S64\u2013S71.","journal-title":"Diabetes Care"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.11607\/jomi.19suppl.g3"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/0022034514538820"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/joor.12435"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijom.2016.05.019"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40729-016-0038-2"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpe.12724"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/jicd.12478"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40729-021-00399-8"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/prd.12451"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2015.04.026"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0028-0"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01517"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.918350"},{"key":"e_1_3_5_17_2","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises label of diabetes drug cagagliflozin (Invokana Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. Available at. http:www.fda.gov\/Drugs\/Drugsafety\/ucm461449.htm (2017)."},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.10.019"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3170"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022577"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-020-00609-z"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042098621989134"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.01.040"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b16-00964"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12985"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/ID.0000000000000021"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0501.2009.01716.x"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-016-0284-1"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.4012\/dmj.27.415"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1600-0501.2003.01015.x"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2009.10.045"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2010.01.016"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4269-4"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2010.07.008"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20194873"}],"container-title":["Bio-Medical Materials and Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09592989261481043","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09592989261481043","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09592989261481043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T21:27:41Z","timestamp":1793568461000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09592989261481043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1177\/09592989261481043"],"URL":"https:\/\/doi.org\/10.1177\/09592989261481043","relation":{},"ISSN":["0959-2989","1878-3619"],"issn-type":[{"value":"0959-2989","type":"print"},{"value":"1878-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]}}}